DHA Supplementation in Patients With STGD3

N/ACompletedNCT00420602

University of Utah11 enrolled

Overview

We have found that biomarkers of long-term elevated dietary intake of omega-3 fatty acids such as DHA and EPA are inversely associated with severity of disease phenotype in STGD3 patients. Therefore, the purpose of this study is to follow STGD3 patients as they supplement their diets with DHA/EPA.

Study Type

INTERVENTIONAL

Allocation

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Dominantly Inherited Stargardt's Disease (STGD3)

Interventions

Over the counter DHA/EPA dietary supplementationDIETARY_SUPPLEMENT

1000 mg/day DHA/EPA

Eligibility

Sex: ALLMin age: 18 YearsMax age: 105 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All Moran Eye Center patients with STGD3 Exclusion Criteria: * All others

Locations (1)

Moran Eye Center, University of Utah

Salt Lake City, Utah, United States

Outcomes

Primary Outcomes

ERG

Time frame: 1 year

Secondary Outcomes

Visual acuity

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.